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S U M M A R Y
Fosfomycin, originally named phosphonomycin, was discovered in Spain in 1969. There are three forms
of fosfomycin: fosfomycin tromethamine (a soluble salt) and fosfomycin calcium for oral use, and
fosfomycin disodium for intravenous use. Fosfomycin is a bactericidal antibiotic that interferes with cell
wall synthesis in both Gram-positive and Gram-negative bacteria by inhibiting the initial step involving
phosphoenolpyruvate synthetase. It has a broad spectrum of activity against a wide range of Gram-
positive and Gram-negative bacteria. It is highly active against Gram-positive pathogens such as
Staphylococcus aureus and Enterococcus, and against Gram-negative bacteria such as Pseudomonas
aeruginosa and Klebsiella pneumoniae. Its unique mechanism of action may provide a synergistic effect to
other classes of antibiotics including beta-lactams, aminoglycosides, and ﬂuoroquinolones. Oral
fosfomycin is mainly used in the treatment of urinary tract infections, particularly those caused by
Escherichia coli and Enterococcus faecalis. Intravenous fosfomycin has been administered in combination
with other antibiotics for the treatment of nosocomial infections due to multidrug-resistant (MDR)
Gram-positive and Gram-negative bacteria. Fosfomycin has good distribution into tissues, achieving
clinically relevant concentrations in serum, kidneys, bladder wall, prostate, lungs, inﬂamed tissues, bone,
cerebrospinal ﬂuid, abscess ﬂuid, and heart valves. Fosfomycin is well tolerated, with a low incidence of
adverse events. Further randomized controlled trials are needed in order to evaluate the efﬁcacy of
intravenous fosfomycin for the management of nosocomial infections due to MDR pathogens.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Fosfomycin, originally named phosphonomycin, was discov-
ered in Spain in 1969.1 It is a phosphonic acid derivative, with an
extremely low molecular weight, and shows almost no binding to
proteins. Fosfomycin is a unique antibiotic that is chemically
unrelated to any other known antibacterial agent. Its empirical
formula is C3H7O4PC4H11NO3 and its chemical structure is shown
in Figure 1.
2. Forms of fosfomycin
Fosfomycin is available in two oral formulations – fosfomycin
tromethamine (synonym trometamol), a soluble salt with im-
proved bioavailability over fosfomycin, which is synthetically
prepared, and fosfomycin calcium. Fosfomycin tromethamine is
the preferred formulation for oral administration of fosfomycin
because it is more readily absorbed into the blood compared to
fosfomycin calcium.2,3 There is also an intravenous formulation –
fosfomycin disodium.* Corresponding author. Tel.: +30 210 6972353; fax: +30 210 6972354.
E-mail address: amichalopoulos@hol.gr (A.S. Michalopoulos).
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doi:10.1016/j.ijid.2011.07.0073. Mechanism of action
Fosfomycin is a bactericidal antibiotic that interferes with cell
wall synthesis in both Gram-positive and Gram-negative bacteria
by inhibiting the initial step involving phosphoenolpyruvate
synthetase. Fosfomycin enters the cells of fosfomycin-susceptible
bacteria by means of two different transport uptake systems: a
constitutively functional L-a-glycerophosphate transport system
(GlpT) and the hexose–phosphate uptake system (UhpT).4 It
inhibits the synthesis of peptidoglycan by blocking the formation
of N-acetylmuramic acid.5
Fosfomycin has a broad spectrum of activity against a wide
range of Gram-positive and Gram-negative bacteria. Its unique
mechanism of action may provide a synergistic effect to other
antibiotics including beta-lactams, aminoglycosides, and ﬂuoro-
quinolones.6–8
4. Pharmacokinetics and pharmacodynamics
Fosfomycin is rapidly absorbed following oral administration
and is converted to the free acid, fosfomycin. Bioavailability is
around 40% for fosfomycin tromethamine vs. 12% for the calcium
salt of fosfomycin; 30–60% of fosfomycin tromethamine is
excreted unchanged in the urine vs. 9–18% for the calcium saltses. Published by Elsevier Ltd. All rights reserved.
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tubular secretion occurs. Fosfomycin has a relatively long
elimination half-life, which varies between 4 and 8 h.10 In patients
with chronic renal failure, the half-life of fosfomycin is increased
signiﬁcantly (up to 50 h) and is associated with a lower fosfomycin
recovery in urine.
Fosfomycin has good distribution into tissues, achieving
clinically relevant concentrations in serum, kidneys, bladder wall,
prostate, lungs, inﬂamed tissues, bone, cerebrospinal ﬂuid, abscess
ﬂuid, and heart valves.11–14 Frossard et al.15 demonstrated high
fosfomycin concentrations in plasma and soft tissues, suggesting a
high degree of tissue penetration. Sauermann et al.16 evaluated
fosfomycin penetration into suppurative lesions to determine
whether it was reaching sufﬁcient concentrations to eradicate
clinically relevant bacteria in abscess ﬂuid. They found that there
was a high inter-individual variability in the pharmacokinetics of
fosfomycin in pus due to highly variable abscess permeability.
They concluded that in many patients, fosfomycin concentration in
abscess ﬂuid would be expected to exceed the minimum inhibitory
concentrations (MIC50/90s) of several relevant bacteria after
multiple doses.
Although fosfomycin crosses maximally into cerebrospinal ﬂuid
(CSF) in the presence of inﬂamed meninges,17 the activity of
fosfomycin against Gram-positive and Gram-negative bacteria is
notably reduced in human CSF.18 Fosfomycin penetrates sufﬁ-
ciently into various tissues and CSF.19 Pfausler et al.20 found that
8 g of fosfomycin three times a day provides sufﬁcient antimicro-
bial concentrations in the CSF in ventriculitis caused by susceptible
pathogens.
5. Susceptibility testing
The agar dilution, broth dilution, and disk diffusion methods are
used in order to determine the in vitro susceptibility of Gram-
positive and Gram-negative bacteria to fosfomycin.21 Agar or broth
dilution testing using Mueller–Hinton agar or broth, respectively,
supplemented with 25 mg/ml glucose-6-phosphate in an aerobic
atmosphere at 35–37 8C is generally recommended.9 However, it
should be noted that some authorities suggest that broth dilution
testing should not be performed to test susceptibility to
fosfomycin.22
In a study by de Cueto et al., the agar dilution, broth
microdilution, and disk diffusion methods were compared to
determine the in vitro susceptibility of 428 extended-spectrum
beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella
pneumoniae to fosfomycin. Fosfomycin showed high activity
against all ESBL-producing strains. Excellent agreement between
the three susceptibility methods was found for E. coli, whereas
marked discrepancies were observed for K. pneumoniae.23
Diffusion techniques requiring measurement of zone diameters
provide reproducible estimates of the susceptibility of bacteria to
fosfomycin. Results of the standard single-disk susceptibility tests
with disks containing 200 mg of fosfomycin and 50 mg of glucose-
6-phosphate should be interpreted according to the following
criteria: zone diameter 16 mm means a susceptible strain; zone
diameter 13–15 mm means an intermediate strain; and zone
diameter 12 mm means a resistant strain.
The MIC values should be interpreted according to the following
criteria: MIC 64 mg/ml: susceptible (S); MIC 128 mg/ml: inter-
mediate (I); MIC 256 mg/ml: resistant (R).
6. Antimicrobial activity
The antimicrobial activity of fosfomycin is broad. Fosfomycin
shows an excellent bactericidal activity against Gram-positive
cocci, such as methicillin-sensitive Staphylococcus aureus (MSSA),cephalosporin- and penicillin-resistant Streptococcus pneumo-
niae,24,25 methicillin-resistant S. aureus (MRSA),26 and Enterococcus
species, even in vancomycin-resistant strains.27 Fosfomycin also
shows very good activity against many Gram-negative bacteria,
such as E. coli, Proteus mirabilis, K. pneumoniae, Enterobacter species,
Citrobacter spp, Serratia marcescens, Neisseria meningitidis, Shigella
spp, and Salmonella typhi, which are generally inhibited at
fosfomycin concentrations of 64 mg/ml. In contrast, Pseudomonas
aeruginosa and Acinetobacter baumannii are usually resistant to
fosfomycin.28–30 The high MIC of fosfomycin against A. baumannii
and P. aeruginosa implies the clinical ineffectiveness of fosfomycin
alone. However, fosfomycin may be effective in combination with
other antibiotics, such as beta-lactam antibiotics (cefepime,
aztreonam, or meropenem) or aminoglycosides.7,8,31–33 It should
be noted that although Bacteroides fragilis is resistant to
fosfomycin, Peptococcus niger and Peptostreptococcus spp are
usually fosfomycin-sensitive. However, fosfomycin is less active
than penicillin, cephalothin, clindamycin, and lincomycin against
these cocci.34
Falagas et al.35 systematically reviewed 17 studies (accounting
for 5057 clinical isolates of Enterobacteriaceae) evaluating the
antimicrobial activity and clinical effectiveness of fosfomycin for
infections caused by multidrug-resistant (MDR) Enterobacteria-
ceae, including ESBL. Eleven studies reported that at least 90% of
the isolates were susceptible to fosfomycin. Using a provisional
MIC susceptibility breakpoint of 64 mg/l or less, the majority of E.
coli and K. pneumoniae isolates producing ESBL were susceptible to
fosfomycin (96.8% and 81.3%, respectively). In two clinical studies,
oral treatment with fosfomycin tromethamine was clinically
effective against complicated and uncomplicated lower urinary
tract infections (UTIs) caused by ESBL-producing E. coli in the
majority of patients. Susceptibility of ESBL-producing K. pneumo-
niae to fosfomycin has also been observed in previous studies.36,37
In addition, the in vitro activity of fosfomycin against blaKPC-
containing K. pneumoniae, including those non-susceptible to
tigecycline or colistin, has been examined by Endimiani et al.38
Samonis et al.39 examined the sensitivity of 594 non-urinary
Gram-negative bacteria. In total, 385 (64.8%) were susceptible to
fosfomycin. Speciﬁcally, all E. coli, Proteus mirabilis, and Salmonella
species isolates were susceptible. In addition, K. pneumoniae
(including carbapenem-resistant strains), Enterobacter species, and
P. aeruginosa isolates were susceptible to fosfomycin (77.7%, 68.8%,
and 64.5%, respectively). Susceptibility was highest amongst
isolates taken from outpatients (73.8%) and lowest for intensive
care unit (ICU) isolates (48.4%). Isolates originating from the
pediatric wards exhibited higher susceptibility (71.4%) than
isolates originating from other departments (64%).
Data from the same hospital dealing with fosfomycin antimi-
crobial activity against Gram-positive non-urinary isolates showed
that 1275 isolates (69.1%) were susceptible to fosfomycin.
Speciﬁcally, S. aureus including MRSA (99.3%) and coagulase-
negative staphylococci (77.5%) were susceptible to fosfomycin.
Among 42 S. pneumoniae, 64 Streptococcus pyogenes, and 93 other
streptococcal isolates, 61.9%, 40.6%, and 48.4%, respectively, were
susceptible to fosfomycin. Fosfomycin was inactive against the 166
enterococcal isolates tested.21
Fosfomycin exerts time-dependent killing against Gram-posi-
tive and Gram-negative bacteria. Bacteria that adhere to foreign
materials, medical devices, implant surfaces, and damaged tissues
can encase themselves in a self-made polymeric matrix of
polysaccharide and protein, forming bioﬁlms. Bioﬁlms play a
signiﬁcant role in the development and persistence of several
nosocomial infections such as central venous catheter-related
infections and urinary catheter-related UTIs. In bioﬁlms, resistance
to antimicrobials is increased. Bioﬁlms facilitate the spread of
antibiotic resistance by promoting horizontal gene transfer.
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bioﬁlms are major contributors to the chronicity of nosocomial
infections. Bacterial bioﬁlms are difﬁcult to detect in routine
diagnostics and are inherently tolerant to host defenses and
several classes of antibiotics. Fosfomycin has shown antimicrobial
activity against bioﬁlms, particularly in combination with ﬂuor-
oquinolones or aminoglycosides.40–43 Based on reports, fosfomycin
can break up bioﬁlms to enhance the permeability of other
antibiotics.44
7. Mechanism of fosfomycin resistance
Bacterial resistance to fosfomycin is exerted by three mecha-
nisms – two of them are located on the chromosome and the third
is of plasmid origin.45 Bacterial resistance to fosfomycin may be
attributed to a genetic mutation in one or both of the
chromosomally encoded transport systems GlpT and/or UhpT,
and less commonly by a fosfomycin-modifying enzyme leading to
products associated with no antibacterial activity.46,47
Plasmid-encoded fosfomycin resistance is exerted by a gene
located in a transposon; it encodes a 16-kilodalton protein located
in the cytoplasm and also encodes constitutive synthesis.48
Plasmid-encoded fosfomycin resistance is due to modiﬁcation of
the antibiotic molecule by an enzyme called metalloglutathione
transferase, a glutathione S-transferase that catalyzes the forma-
tion of a covalent bond between the sulfhydryl residue of the
cysteine in glutathione and C-1 of fosfomycin.49,50 Four fosfomy-
cin-modifying enzymes have already been described. These
enzymes catalyze the formation of a glutathione–fosfomycin
(FosA), L-cysteine–fosfomycin (FosB), ATP–fosfomycin (FosC), and
water–fosfomycin (FosX) adducts.51 FosA is a Mn(II)- and K+-
dependent glutathione transferase.52 FosB is a Mg2+-dependent L-
cysteine thiol transferase. FosX is a Mn(II)-dependent fosfomycin-
speciﬁc epoxide hydrolase.53 The metalloglutathione transferase
FosA catalyzes the conjugation of glutathione to C-1 of fosfomycin,
rendering it ineffective as an antibacterial agent.46 The plasmid-
mediated fosfomycin glutathione S-transferase genes fosA and fosB
have been found in a low percentage of isolated strains.54
The development of cross-resistance to fosfomycin by the use of
other classes of antibacterial agents such as beta-lactams and
aminoglycosides has not been regarded as signiﬁcant, probably
due to the unique target of action of fosfomycin.55
8. Clinical use
8.1. Oral fosfomycin in UTIs
Fosfomycin is mainly used in the treatment of UTIs, particularly
those caused by E. coli and Enterococcus faecalis, and in combination
with other antibiotics in the treatment of nosocomial infections
due to resistant Gram-positive and Gram-negative bacteria.41,55–57
In most European countries, oral fosfomycin has been used for
many years, mainly in the treatment of uncomplicated cystitis or
other UTIs, particularly those caused by E. coli and E. faecalis. In the
USA, the Food and Drug Administration has approved oral
fosfomycin only for uncomplicated UTIs.
Rudenko and Dorofeyev58 examined 317 non-pregnant females
suffering from recurrent lower UTIs (at least three episodes in the
preceding 12 months) in order to assess the efﬁcacy and safety of
fosfomycin tromethamine in the prevention of infectious recur-
rences of lower UTIs. One hundred and sixty-six patients were
randomized to receive fosfomycin treatment and 151 to receive
placebo treatment. Patients received 3 g fosfomycin or placebo
every 10 days for 6 months. Thereafter they were followed up for
another 6 consecutive months. They found 0.14 infections per
patient per year in the fosfomycin group and 2.97 infections perpatient per year in the placebo group (p < 0.001). The time to ﬁrst
infection recurrence was signiﬁcantly longer in the fosfomycin
group (38 days) than in the placebo group (6 days) (p < 0.01). The
number of patients with at least one episode of recurrent infection
and the number of episodes per patient during treatment as well as
during the follow-up period were signiﬁcantly lower in the
fosfomycin group than in the placebo group.
Falagas et al.59 reported the results of their meta-analysis of 27
randomized controlled trials (RCTs) dealing with the effectiveness
and safety of fosfomycin for the treatment of cystitis in pregnant
and non-pregnant women. Twenty-seven trials (eight double-
blind) were included. Sixteen of these trials involved exclusively
non-pregnant female patients and ﬁve involved pregnant patients.
Regarding clinical success, no difference was found in the
comprehensive analysis regarding all comparators combined in
trials involving non-pregnant females, while insufﬁcient relevant
data were provided from trials involving pregnant patients. No
difference between fosfomycin and comparators was also found in
all comparisons regarding the remaining effectiveness outcomes,
namely microbiological success/relapse/re-infection. Fosfomycin
had a comparable safety proﬁle to the evaluated comparators in
non-pregnant women, whereas it was associated with signiﬁcantly
fewer adverse events in pregnant women.
Pullukcu et al.60 examined the effect of fosfomycin trometha-
mine in the treatment of ESBL-producing E. coli-related lower UTI
in 52 adult patients receiving 3 g per day fosfomycin trometha-
mine, three times. Overall clinical success was 94.3% and
microbiological success was 78.5%. Similar good results have been
reported from a recent Spanish clinical study.61
A single dose of fosfomycin tromethamine is well absorbed and
produces a therapeutic concentration in the urine for 1–3 days.
Comparative clinical trials suggest that a single 3-g dose of
fosfomycin tromethamine is as clinically effective as 7- to 10-day
treatment regimens of standard agents such as nitrofurantoin,
norﬂoxacin, and trimethoprim/sulfamethoxazole used to treat
UTIs. Fosfomycin tromethamine is well tolerated and appears safe
for use during pregnancy.62 According to Schito, fosfomycin
tromethamine remains a reliable therapeutic option for uncom-
plicated UTI due to its main advantages, including single dose
usage and very high and sustained urinary concentrations that
rapidly kill bacteria, reducing the opportunity for mutant selection.
In addition there is no animal feed that contains the drug,
resistance is most commonly acquired by chromosomal mutations
that do not spread easily, and the biological cost of these genetic
modiﬁcations is high. In addition, fosfomycin tromethamine has
excellent tolerability and safety.63
8.2. Intravenous fosfomycin in clinical use
Regarding the intravenous administration of fosfomycin,
Falagas et al.2 studied 1604 patients with Gram-positive and
Gram-negative infections (including pneumonia, osteomyelitis,
meningitis, surgical infections, obstetric and gynecological infec-
tions, arthritis, sepsis, peritonitis, cervical lymphadenitis, ear, nose,
and throat infections, eye infections, diabetic foot infections, and
typhoid fever). Patients were treated with intravenous fosfomycin
alone or in combination with other antibiotics. Cure was achieved
in 81.1% of patients and improvement in approximately 3%.
Recently, intravenous fosfomycin has been administered in
critically ill patients with sepsis or nosocomial-acquired infections
due to MRSA, vancomycin-resistant Enterococcus, and MDR Gram-
negative bacteria, especially carbapenem-resistant K. pneumoniae,
in combination with other antibiotics, due to its unique mecha-
nism of action and its protective effect against nephrotoxicity
induced by aminoglycosides or colistin.64–66 Michalopoulos et al.65
examined the effectiveness and safety of fosfomycin in critically ill
Figure 1. Chemical structure of fosfomycin.
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nem-resistant K. pneumoniae. They concluded that fosfomycin may
be considered an alternative for the treatment of infections due to
carbapenem-resistant K. pneumoniae in adult patients, especially
in combination with other antibiotics. Data also suggest that the
intravenous formulation of fosfomycin could be useful for eye
infections.67
One rationale for combining fosfomycin with a second
antimicrobial agent is to prevent the emergence of fosfomycin-
resistant strains. Fosfomycin has regained attention because of its
in vitro activity against ESBL-producing Enterobacteriaceae and
MDR P. aeruginosa. Clinical studies dealing with the intravenous
administration of fosfomycin for curative use in adult patients are
listed in Table 1. It should be noted that the clinical utility of
fosfomycin in nosocomial infections due to MDR Gram-negative
bacteria should be explored further in future RCTs.
Fosfomycin is approved in several European countries for the
therapy of soft-tissue infections and sepsis.68 However, it should
be noted that the intravenous formulation of fosfomycin is
available in ﬁve countries in Europe – Spain, France, Germany,
Austria, and Greece.
All studies dealing with the curative use of intravenous
fosfomycin in adult patients are presented in Table 1.33,65,66,69–84
8.3. Fosfomycin for surgical prophylaxis
Ishizaka et al.85 compared the efﬁcacy of fosfomycin (2 g/dose)
and cefotiam (1 g/dose), both administered intravenously 30 min
before surgery, for preventing postoperative infections in patients
undergoing urological surgery. Both antibiotics were administeredTable 1
Studies dealing with the curative use of fosfomycin in adult patients (intravenous adm
Study Patients (n) Age, mean
years
Pathogens 
Alvarez et al.71 1 - Serratia marcescens 
Boulard et al.72 4 - Staphylococcus epidermidis 
Bureau-Chalot et al.73 1 - Stomatococcus mucilaginosus 
Florent et al.70 72 55 Multiple 
Gillard et al.74 8 - - 
Guerin et al.75 1 46 Pseudomonas aeruginosa 
May et al.76 7 - Multiple 
Meissner et al.69 60 37.4 Multiple 
Michalopoulos et al.65 11 67.5 MDR Klebsiella pneumoniae 
Mirakhur et al.33 15 23 Pseudomonas aeruginosa 
Nakayama et al.77 1 64 MRSA 
Nissen et al.78 17 - Multiple 
Ortler et al.79 1 35 Staphylococcus aureus 
Portier et al.80 16 - MRSA 
Roualdes et al.81 2 - Staphylococcus epidermidis,
Staphylococcus capitis,
Micrococcus varians
Silbermann et al.82 1 17 Staphylococcus epidermidis 
Ueda et al.83 65 - Multiple 
Yamaguchi et al.66 1 64 MRSA 
Zink et al.84 1 81 Staphylococcus albus 
a Eighteen patients received usually a ﬂuoroquinolone with a beta-lactam or fosfomtwice daily for 3 days after surgery. The reduction in the rate of
surgical site infections was 90.8% overall – 90.5% for fosfomycin
and 91.0% for cefotiam. Fosfomycin and cefotiam response rates
were 92.9% and 94.9%, respectively, in transurethral surgery
patients, and 87.2% and 85.4%, respectively, in patients undergoing
open-surgery (consisting of clean surgery, clean-contaminated
surgery, and contaminated surgery). The surgical-site infection
rates in open surgery were 0% for fosfomycin and 4.9% for cefotiam.
However, no statistically signiﬁcant difference was found.
In comparative peri-operative prophylaxis trials that included
1212 patients (mainly undergoing colorectal surgery), the
fosfomycin–metronidazole combination led to results similar to
those achieved with the combination of other antibiotics, such as
doxycycline, ampicillin, or cephalothin and metronidazole. The
authors concluded that fosfomycin might be considered as an
alternative agent for infections caused by sensitive Gram-positive
and Gram-negative bacteria, in addition to its traditional use in
treating uncomplicated urinary tract and gastrointestinal infec-
tions.2Clinical studies dealing with the intravenous administration
of fosfomycin for surgical prophylaxis in adult patients are shown
in Table 2.85–91
9. Dosing
9.1. Oral fosfomycin
The usual oral dose of fosfomycin calcium is the equivalent of
0.5–1 g of fosfomycin administered every 6–8 h. Higher doses
should be given parenterally. For uncomplicated cystitis, a single
dose of fosfomycin (3 g) is adequate. For complicated cystitis, a
single dose of fosfomycin (3 g) administered every 2–3 days is
necessary. In total, three doses of fosfomycin are needed. In the
case of oral administration, no dosage adjustment is necessary in
patients with hepatic or renal failure.
9.2. Intravenous fosfomycin
Several regimens of intravenous fosfomycin are used world-
wide. Fosfomycin disodium is given intravenously and on rare
occasions intramuscularly. The daily dose ranges from 12 to 16 g
on average, administered in 2–4 infusions. Daily doses of up to 20 ginistration)
Infection Combination therapy Mortality (%)
Endophthalmitis Ceftriaxone + amikacin 0
CSF shunt infection Aminoglycoside 0
Spondylodiscitis Cefotaxime 0
Multiple Multiple 13
Pyogenic discitis Quinolonea 0
Prostatitis Aztreonam 0
Meningitis Ceftriaxone -
Chronic osteomyelitis No combination therapy 26.4
ICU-acquired infection Multiple 18.2
Cystic ﬁbrosis Multiple 0
Toxic shock syndrome Vancomycin 0
Pneumonia Ampicillin 6
Wound infection Cefmenoxime 0
Bacteremia; bone/
joint infection/meningitis
Cefotaxime 0
CSF shunt infection Vancomycin, rifampin 0
Meningitis Vancomycin 0
Multiple 0 46.1
Pneumonia and sepsis Arbekacin 0
Ventriculoatrial shunt meningitis Gentamicin 0
ycin.
Table 2
Studies dealing with intravenous administration of fosfomycin for surgical prophylaxis in adult patients
Study RCT Type of surgery Patients (n) Combination of antibiotics Post-op infection rate
Anda˚ker et al.86 Yes Elective colorectal 559 Yes (metronidazole) Abdominal infection (4.6%);
remote infection (15.1%)
Anda˚ker et al.87 Yes Emergency abdominal 381 Yes (metronidazole) Sepsis (1.6%)
Ishizaka et al.85 Yes Urologic 95 No 9.5%
Lebreton et al.88 No Open heart surgery 34 Yes (peﬂoxacin) 5.9%
Lindhagen et al.89 Yes Colorectal 49 Yes (metronidazole) Sepsis (0%)
Nøhr et al.90 Yes Elective colorectal 72 Yes (metronidazole) 13%
Shinagawa et al.91 No Upper gastroenterological
and hepatobiliary surgery
162 No 13.2%
RCT, randomized controlled trial.
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infections. Renal impairment signiﬁcantly decreases the excretion
of fosfomycin. For intravenous administration of fosfomycin, the
doses should be reduced if the creatinine clearance is less than
50 ml/min.
10. Contraindications and adverse effects
Hypersensitivity to fosfomycin or any components of its
formulation are the main contraindications for its administra-
tion.92
10.1. Oral fosfomycin
Oral fosfomycin is well tolerated with a low incidence of
adverse events. These comprise mainly gastrointestinal symptoms
that are transient, mild, and self-limiting,93 and include diarrhea
(10%), nausea (5%), abdominal pain (2%), and dyspepsia (1–2%).
Other adverse effects include headache, dizziness, back pain,
weakness, vaginitis, rhinitis, and pharyngitis. Signiﬁcant laborato-
ry alterations reported include an increased eosinophil count,
increased or decreased white blood cell count, increased bilirubin,
increased alanine aminotransferase, increased aspartate amino-
transferase, increased alkaline phosphatase, decreased hematocrit,
decreased hemoglobin, and alterations in platelet count. Changes
have generally been transient and not clinically signiﬁcant.
Fosfomycin is not a nephrotoxic agent. Previous studies
performed in animals have shown that fosfomycin has a protective
effect against nephrotoxicity due to aminoglycosides, by inhibiting
aminoglycoside-induced histamine release from mast cell destruc-
tion.94 The prolonged use of oral fosfomycin may result in fungal or
bacterial superinfections, including rare Clostridium difﬁcile-
associated diarrhea and pseudomembranous colitis.95 It should
be noted that the adverse events associated with fosfomycin do not
usually necessitate the discontinuation of treatment.
10.2. Intravenous fosfomycin
The intravenous administration of fosfomycin is associated
with a low incidence of adverse effects. The most signiﬁcant
adverse effect related to the administration of fosfomycin
disodium is a high sodium intake, which could be a limitation
in patients with heart or renal failure. It should be emphasized that
1 g of intravenous fosfomycin brings 0.33 g (14.4 mEq) of sodium.
Other adverse effects reported rarely are allergic reactions, nausea,
neutropenia, hypereosinophilia, and local phlebitis.33,69 Recently,
Florent et al.70 reported adverse effects associated with intrave-
nous fosfomycin administered in 72 patients. Hypokalemia was
the most common (26%), followed by injection-site reaction (pain)
seen in 4% and heart failure or hypertension in 3% of patients.
However, these adverse effects are usually mild, tolerable, and
transient.11. Drug interactions
Scarce data are available regarding fosfomycin interactions. A
total of two drugs are known to interact with fosfomycin:
balsalazide, which interacts with the oral formulation of fosfo-
mycin (moderate interaction), and metoclopramide (mild interac-
tion). The latter, when given concomitantly with fosfomycin, may
lead to a lower serum concentration and urinary excretion of
fosfomycin. The mechanism of action appears to be due to
increased gastrointestinal mobility.96
12. Synergistic activity
The efﬁcacy of a fosfomycin combination with a second
antibiotic against S. aureus and E. faecalis has been evaluated in
vitro and in vivo.97–101 A number of previous studies have shown
that fosfomycin can act synergistically with beta-lactams and with
aminoglycosides.8,102,103
13. Immunomodulatory effects
Fosfomycin exerts immunomodulatory effects, mainly on
lymphocyte and neutrophil function.104 It has been suggested
that fosfomycin, in addition to its antimicrobial activity, exhibits
immunomodulatory effects on lipopolysaccharide-stimulated
monocytes and T-lymphocytes. It appears that the action of
fosfomycin on T-cells involves a suppression of interleukin (IL)-2
production.105 Fosfomycin also has an immunomodulatory effect
on B-cell activation. Honda et al. reported that fosfomycin
suppresses both the production of leukotriene B4 (LTB4) from
neutrophils and the expression of IL-8 mRNA by LTB4 from
monocytes.106
Previous studies have shown that fosfomycin also affects the
acute inﬂammatory cytokine response in vitro and in vivo.107–109
Fosfomycin modulates the in vivo production of inﬂammatory
cytokines, such as tumor necrosis factor (TNF)-a, IL-1b, and IL-
6.110 However, Sauermann et al.111 evaluated the effect of
fosfomycin on proinﬂammatory cytokines in healthy volunteers.
They found that the concentrations of TNF-a, IL-1b, and IL-6
expressed as protein and mRNA levels were almost identical with
and without fosfomycin.
Pe´rez Ferna´ndez et al.112 found that fosfomycin enhances the
phagocytic killing of invading pathogens by host cells. Similarly,
Tullio et al.113 reported that fosfomycin was able to induce the
enhancement of the depressed phagocytic response of polymor-
phonuclear cells in patients on chronic hemodialysis and renal
transplant recipients, restoring their primary functions in vitro
against ESBL-producing E. coli. In addition, Krause et al.114
investigated the effect of fosfomycin on neutrophil function.
Fosfomycin incubation resulted in enhanced bactericidal ability,
increased intracellular calcium concentrations, elevated extracel-
lular reactive oxygen intermediate (ROI) production, and de-
A.S. Michalopoulos et al. / International Journal of Infectious Diseases 15 (2011) e732–e739 e737creased chemotaxis, but did not affect intracellular ROI production
and chemokinesis.
14. Conclusions
Fosfomycin is a bactericidal antibiotic with a broad spectrum of
activity against a wide range of Gram-positive and Gram-negative
bacteria. It presents good distribution into several tissues. It has a
unique mechanism of action that may provide a synergistic effect
to other antibiotics, including beta-lactams, aminoglycosides, and
ﬂuoroquinolones. Oral fosfomycin is used in the treatment of UTIs,
mainly those caused by E. coli and E. faecalis. Intravenous
fosfomycin has been administered in combination with other
antibiotics for the treatment of nosocomial infections due to MDR
Gram-positive and Gram-negative bacteria in daily doses ranging
from 12 to 20 g. The intravenous administration of fosfomycin is
associated with a low incidence of adverse effects. Further RCTs are
needed to evaluate the efﬁcacy of intravenous fosfomycin for the
management of infections due to MDR pathogens.
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